MedTrace Logo

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

NCT02192554 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2018-04-30

No results posted yet for this study

Summary

To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.

Conditions

  • Agitation Associated With Alzheimer's Disease
  • Alzheimer's Type
  • Mental Disorder
  • Nervous System Diseases

Sponsors & Collaborators

  • H. Lundbeck A/S

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Eva Kohegyi, MD, MS · Otsuka Pharmaceutical Development & Commercialization, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • United States
  • Bulgaria
  • Canada
  • Croatia
  • France
  • Germany
  • Russia
  • Serbia
  • Slovenia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02192554 on ClinicalTrials.gov